More than 60% of those who responded to the treatment and 76% of those who achieved a complete response experienced no complications or cancer progression a year after treatment.

**ABSTRACT 463 (GOLDSCHMIDT)**
Immune-Boosting Antibody Treatment Isatuximab Meets Primary Endpoint for Multiple Myeloma

Participants who achieved minimal residual disease negativity in the bone marrow after their induction treatment

51.1% of those who received isatuximab-RVD

35.6% of those who received RVD only

**ABSTRACT 127 (BUDDE)**
Bispecific Antibody Mosunetuzumab Brings Deep Remission for Follicular Lymphoma

A phase I/II trial for the experimental drug mosunetuzumab met its primary endpoint, leading to deep, durable remissions for patients with relapsed or refractory follicular lymphoma

More than 60% of those who responded to the treatment and 78% of those who achieved a complete response experienced no complications or cancer progression a year after treatment.

**ABSTRACT 91 (KAMDAR)**
TRANSFORM Study Reports CAR T-cell Therapy Liso-cel Significantly Improves Outcomes for Relapsed and Refractory Large B-cell Lymphoma

Patients receiving CAR T-cell therapy survived for a median of 7.8 MONTHS LONGER WITHOUT COMPLICATIONS OR CANCER PROGRESSION than those receiving standard of care

Median months of event-free survival for patients receiving:

- CAR T-CELL THERAPY: 10.1
- STANDARD OF CARE: 2.3

**ABSTRACT 2 (LOCKE)**
ZUMA-7 Demonstrates Lasting Benefits of CAR-T Therapy Over Current Standard of Care for Large B-cell Lymphoma

The trial enrolled patients with early relapsed or refractory large B-cell lymphoma who had previously undergone front-line chemotherapy and were intended to proceed to stem cell transplantation.

83% of patients receiving AXI-CEL responded to treatment

50% of patients receiving standard of care responded to treatment

**IMMUNE SYSTEM 1, CANCER 0: ADVANCES IN IMMUNOTHERAPY**

“These studies highlight major areas of investigation that are ongoing in cancer care and treatment. They will certainly garner a lot of interest and, in some cases, will likely transform practice.”

LAURIE SEHN, MD
British Columbia Cancer Centre for Lymphoid Cancer and The University of British Columbia

"IMMUNE SYSTEM 1, CANCER 0: ADVANCES IN IMMUNOTHERAPY"

These studies highlight major areas of investigation that are ongoing in cancer care and treatment. They will certainly garner a lot of interest and, in some cases, will likely transform practice.”

LAURIE SEHN, MD
British Columbia Cancer Centre for Lymphoid Cancer and The University of British Columbia

2021 PRESS BRIEFING HIGHLIGHTS
63rd ASH Annual Meeting & Exposition